Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies
Alzheimer's & Dementia · 2025-07 · 21 (7)
DOI: 10.1002/alz.70470 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 19.07.2025. Verfasst von Jennifer G Goldman und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Division, JPG Enterprises LLC, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Lewy Body Disease, Prodromal Symptoms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, Lewy Body Dementia Association.
Themen: Demenz
Abstract (Originalsprache)
Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society. Despite its frequency, diagnosing and treating DLB remains challenging. Advances in in vivo biomarker assays reflecting underlying pathology are improving disease identification, diagnostic accuracy, and therapeutic development for biologically targeted, disease‐modifying agents. Consequently, definitions of Alzheimer's disease and Parkinson's disease (PD) have shifted to focus on pathological changes occurring before clinical features, with proposed frameworks for detecting pathological amyloid and tau, neurodegeneration, and other markers (National Institute on Aging‐Alzheimer's Association) and alpha‐synucleinopathy and dopaminergic degeneration (Neuronal α‐synuclein Disease Integrated Staging System, SynNeurGe). The biological frameworks, particularly those related to alpha‐synuclein (α‐synuclein), have sparked debate about unifying DLB and PD under a single pathobiologic disease. This paper discusses the implications of these biological frameworks for the DLB community, addressing topics regarding multiple pathologies and neurochemical systems, clinical heterogeneity, and functional impairment, and exploring the potential impact on clinical trials and care. Highlights DLB is a progressive neurodegenerative disease with varied clinical presentations. Diagnosing and treating DLB remains challenging despite its frequency. Biological frameworks are reshaping Alzheimer's and Parkinson's definitions. In vivo biomarkers are improving DLB identification and diagnostic accuracy. Debate exists regarding unifying DLB and Parkinson's under one pathobiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Division, JPG Enterprises LLC, Chicago, Illinois, USA.
- Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.
- Department of Neurology and Center for Sleep Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurosciences, UC San Diego, La Jolla, California, USA.
- Biomedical Research Building, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK.
- Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, Florida, USA.
ORCID-Profile: Jennifer G Goldman
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- Lewy Body Dementia Association
Zitieren
APA
Goldman, J. G., Boeve, B. F., Galasko, D., Taylor, J. P., Galvin, J. E., Leverenz, J. B., Blanc, F., Halliday, G., Kantarci, K., Lemstra, A. W., Leroi, I., Lewis, S. J. G., Litvan, I., Medsger, H., O'Brien, J., Scholz, S. W., Aarsland, D., Ikeda, M., McKeith, I., & Taylor, A. (2025). Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies. Alzheimer's & Dementia, 21(7). https://doi.org/10.1002/alz.70470
Vancouver
Goldman JG, Boeve BF, Galasko D, Taylor JP, Galvin JE, Leverenz JB, et al. Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies. Alzheimer's & Dementia. 2025;21(7). doi:10.1002/alz.70470
BibTeX
@article{Goldman2025,
author = {Goldman, Jennifer G and Boeve, Bradley F and Galasko, Douglas and Taylor, John-Paul and Galvin, James E and Leverenz, James B and Blanc, Frederic and Halliday, Glenda and Kantarci, Kejal and Lemstra, Afina W and Leroi, Iracema and Lewis, Simon J G and Litvan, Irene and Medsger, Helen and O'Brien, John and Scholz, Sonja W and Aarsland, Dag and Ikeda, Manabu and McKeith, Ian and Taylor, Angela},
title = {Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {7},
doi = {10.1002/alz.70470}
}
EUVIMED